Aptorum Group (APM) - Long-Term Debt to Capital

Robotic molecule screening allows Aptorum Group Limited (APM) to manage multiple projects with a small staff, which is reflected in the long-term liabilities-to-equity ratio on the GURU.Markets chart; meanwhile, the 0.00 metric indicates the status of the financial leverage. The company relies on AI platforms for rare disease drug design while maintaining an academic image as a reliable developer in oncology.

Aptorum Group Limited focuses on developing innovative phytopharmaceuticals to combat cancer and infections. The dynamics of the company's long-term debt-to-equity ratio reflect the dependence of R&D processes on borrowed funds. This indicator is calculated as the ratio of loans with a maturity of over one year to total equity. A decrease in this coefficient minimizes financial risks but may indicate a slowdown in the pace of clinical trials. An optimal balance of this metric ensures business stability when scaling therapeutic products.